With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.147497-32-3,6-Bromo-3,4-dihydroisoquinolin-1(2H)-one,as a common compound, the synthetic route is as follows.
10445] NaH (0.42 g, 17.7 mmol) was added to an ice-cold solution ofproduct of Example l (2 g, 8.8 mmol) in THF (40 ml) portion wise, and the mixture was stirred for 15 mm. Ethyl bromo acetate (2.2 g, 13.2 mmol) was then added to the solution, and the mixture was stirred at room temperature for 3 h. Reaction mixture was quenched with ice-cold water and diluted with ethyl acetate. Organic layer was separated, washed with brine, dried over Na2SO4 and filtered. The filtrate was concentrated under vacuum to afford title compound (3.3 g, 80%) as solid. ?H NMR (300 MHz, CDC13): oe 7.93 (d, J=8.4 Hz, 1H), 7.47 (d, J=8.4 Hz, 1H), 7.36 (s, 2H),4.24 (q, J=7.2 Hz, 2H), 3.65 (t, J=7.2 Hz, 2H), 3.04 (t, J=7.2 Hz, 2H), 1.28 (t, J=7.2 Hz, 3H).
147497-32-3, 147497-32-3 6-Bromo-3,4-dihydroisoquinolin-1(2H)-one 21865450, aisoquinoline compound, is more and more widely used in various fields.
Reference£º
Patent; GlaxoSmith Kline Intellectual Property (No.2) Limited; Christensen, IV, Siegfried Benjamin; Qin, Donghui; JOSHI, Hemant; Tangirala, Raghuram S.; US2015/307445; (2015); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem